SCM
PTCT icon

Scopia Capital Management’s PTC Therapeutics PTCT Stock Holding History

Scopia Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-871,780
Closed -$29.5M – 24
2019
Q3 		$29.5M Sell
871,780
-111,225
-11% -$4.84M 1.73% 16
2019
Q2 		$44.2M Sell
983,005
-1,123,185
-53% -$44.4M 1.96% 17
2019
Q1 		$79.3M Buy
2,106,190
+479,225
+29% +$16.1M 2.93% 15
2018
Q4 		$55.8M Buy
1,626,965
+9,967
+0.6% +$358K 1.89% 18
2018
Q3 		$76M Sell
1,616,998
-686,343
-30% -$28.4M 1.46% 22
2018
Q2 		$77.7M Sell
2,303,341
-3,610,711
-61% -$113M 1.36% 26
2018
Q1 		$160M Buy
5,914,052
+1,770,782
+43% +$44.9M 3.2% 15
2017
Q4 		$69.1M Buy
4,143,270
+2,949,141
+247% +$49.9M 1.24% 26
2017
Q3 		$23.9M Buy
+1,194,129
New +$23.4M 0.38% 27

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Scopia Capital Management's PTCT Position: Q4 2019 in Review

Scopia Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 871,780 shares — an estimated $29.5M sold.

Scopia Capital Management first reported a position in PTCT in Q3 2017 and held it in 9 quarters. The position peaked at $160M in Q1 2018. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

  • Scopia Capital Management reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Scopia Capital Management sold 871,780 PTC Therapeutics shares in Q4 2019, an estimated $29.5M.
  • Scopia Capital Management first reported a position in PTC Therapeutics in Q3 2017 and held it in 9 quarters.
  • Scopia Capital Management's PTC Therapeutics position peaked at $160M in Q1 2018.
  • 206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Scopia Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.